Neptune Medical vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 34)
Neptune Medical logo

Neptune Medical

EmergingHealthcare

Minimally Invasive Endoscopic Devices

Neptune Medical develops the Pathfinder endoscopy platform using Dynamic Rigidization technology, allowing flexible endoscopes to become rigid on demand for improved procedural control; FDA-cleared; targeting colonoscopy and small bowel procedures;

AI VisibilityBeta
Overall Score
D34
Category Rank
#571 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
36
Perplexity
36
Gemini
33

About

Neptune Medical is a medical device company founded in 2015 and headquartered in Redwood City, California, that is developing a new category of endoscopic access technology. Its flagship product, the Pathfinder system, is built on proprietary Dynamic Rigidization technology — a mechanism that allows a flexible endoscope or access sheath to toggle between a soft, navigable state and a firm, rigid state in real time during a procedure. This on-demand rigidity addresses a fundamental limitation of standard flexible endoscopy: once a scope is advanced into a complex anatomy, it loses pushability and control because the soft shaft cannot transmit force efficiently. Pathfinder restores that mechanical advantage without requiring a separate rigid instrument.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
up
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

34
Overall Score
90
#571
Category Rank
#2
83
AI Consensus
83
stable
Trend
up
36
ChatGPT
92
36
Perplexity
93
33
Gemini
89
38
Claude
96
31
Grok
95

Key Details

Category
Minimally Invasive Endoscopic Devices
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.